Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target.
Wang H, Tang S, Wu Q, He Y, Zhu W, Xie X, Qin Z, Wang X, Zhou S, Yao S, Xu X, Guo C, Tong X, Han S, Chou YH, Wang Y, Wong KK, Yang CG, Chen L, Hu L, Ji H.
Wang H, et al. Among authors: wu q.
Natl Sci Rev. 2024 Nov 7;11(12):nwae392. doi: 10.1093/nsr/nwae392. eCollection 2024 Dec.
Natl Sci Rev. 2024.
PMID: 39687207
Free PMC article.